Skip to main content

GENES Y VIAS DE SEÑALIZACION EMERGENTES EN EL DESARROLLO Y EL CANCER DE TIROIDES

SAF2016-75531-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 28
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Key signaling pathways in thyroid cancer

  • Zaballos, Miguel A.
  • Santisteban, Pilar
Whole genome sequencing approaches have provided unprecedented insights into the genetic lesions responsible for the onset, progression and dedifferentiation of various types of thyroid carcinomas. Through these efforts, the MAPK and PI3K signaling cascades have emerged as the main activation pathways implicated in thyroid tumorigenesis. The nature of these essential pathways is highly complex, with hundreds of components, multiple points of crosstalk, different subcellular localizations and with the ability to potentially regulate many cellular processes. Small-molecule inhibitors targeting key kinases of these pathways hold great promise as novel therapeutics and several have reached clinical trials. However, while some remarkable responses have been reported, the development of resistance remains a matter of concern and limits the benefit for patients. In this review, we discuss the latest findings on the major components of the MAPK and PI3K pathways, including their mechanisms of activation in physiological and pathological contexts, their genetic alterations with respect to the different types of thyroid carcinomas and the more relevant drugs designed to block their activity., Supported by the following grants: GCB14142311CRES from the Spanish Foundation against Cancer (F-AECC), SAF2013-44709-R and SAF2016-75531-R from the Ministry of Economy and Competitiveness, RD12/0036/0030 and Ciberonc from the Carlos III Health Institute, (Spain), and the European Regional Development Fund (FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer

  • Wang, Fei
  • Zhao, Shihua
  • Shen, Xiaopei
  • Zhu, Guangwu
  • Liu, Rengyun
  • Viola, David
  • Elisei, Rossella
  • Puxeddu, Efisio
  • Fugazzola, Laura
  • Colombo, Carla
  • Jarzab, Barbara
  • Czarniecka, Agnieszka
  • Lam, Alfred K.
  • Mian, Caterina
  • Vianello, Federica
  • Yip, Linwah
  • Riesco-Eizaguirre, Garcilaso
  • Santisteban, Pilar
  • O’Neill, Christine J.
  • Sywak, Mark S.
  • Clifton-Bligh, Roderick
  • Bendlova, Bela
  • Sýkorová, Vlasta
  • Wang, Yangang
  • Xing, Mingzhao
[Purpose]: To test whether the prognostic risk of male sex in papillary thyroid cancer (PTC) is determined by BRAF V600E and can thus be stratified by BRAF status. [Patients and Methods]: We retrospectively investigated the relationship between male sex and clinicopathologic outcomes in PTC, particularly mortality, with respect to BRAF status in 2,638 patients (male, n = 623; female, n = 2,015) from 11 centers in six countries, with median age of 46 years (interquartile range, 35-58 years) at diagnosis and median follow-up time of 58 months (interquartile range, 26-107 months). [Results]: Distant metastasis rates in men and women were not different in wild-type BRAF PTC but were different in BRAF V600E PTC: 8.9% (24 of 270) and 3.7% (30 of 817; P = .001), respectively. In wild-type BRAF PTC, mortality rates were 1.4% (five of 349) versus 0.9% (11 of 1175) in men versus women (P = .384), with a hazard ratio (HR) of 1.59 (95% CI, 0.55 to 4.57), which remained insignificant at 0.70 (95% CI, 0.23 to 2.09) after clinicopathologic multivariable adjustment. In BRAF V600E PTC, mortality rates were 6.6% (18 of 272) versus 2.9% (24 of 822) in men versus women (P = .006), with an HR of 2.43 (95% CI, 1.30 to 4.53), which remained significant at 2.74 (95% CI, 1.38 to 5.43) after multivariable adjustment. In conventional-variant PTC, male sex similarly had no effect in wild-type BRAF patients; mortality rates in BRAF V600E patients were 7.2% (16 of 221) versus 2.9% (19 of 662) in men versus women (P = .004), with an HR of 2.86 (95% CI, 1.45 to 5.67), which remained significant at 3.51 (95% CI, 1.62 to 7.63) after multivariable adjustment. [Conclusion]: Male sex is a robust independent risk factor for PTC-specific mortality in BRAF V600E patients but not in wild-type BRAF patients. The prognostic risk of male sex in PTC can thus be stratified by BRAF status in clinical application., Supported by US National Institutes of Health (NIH) Grants No. R01CA215142 and R01CA189224 (M.X.) and by the following additional funding at the individual participating centers: Polish National Center of Research and Development MILESTONE (Molecular Diagnostics and Imaging in Individualized Therapy for Breast, Thyroid and Prostate Cancer) Project Grant No. STRATEGMED2/267398/4/NCBR/2015 (A.C., B.J.); grants from the Menzies Health Institute, Griffith University, Queensland Cancer Council, and Queensland Smart State Fellowship in Australia (A.K.L.); Ministry of Economy and Competitiveness (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) Grant No. SAF2016- 75531-R, Instituto de Salud Carlos III Grant No. PI14/01980, Asociación Española Contra el Cáncer Foundation Grant No. GCB14142311CRES, and TIRONET2-CM Grant No. B2017/BMD-3724 TIRONET2-CM in Spain (P.S., G.R.-E.); Institute of Endocrinology Grants No. AZV 16-32665A and MH CZ-DRO in the Czech Republic (B.B., V.S.); grants from the New South Wales Cancer Institute (C.J.O.) and Cancer Council of New South Wales (R.C.-B.) in Australia; National Institute on Aging, NIH, Grant No. 5R03AG042334-02 (L.Y.); grants from the Ministero della Istruzione Universitaria e Ricerca Scientifica, the Associazione Italiana per la Ricerca sul Cancro, the Istituto Toscano Tumori, and the Ministero della Salute in Italy (D.V., R.E.); and Grant No. 13-1-3-58-nsh from the Qingdao Science and Technology Project for People’s Livelihood (F.W., S.Z.), Shandong Outstanding Young Scientist Award Grant No. BS2009YY030 (F.W.), Grant No. 2013 WS0266 from the Health Department of Shandong Province (S.Z., F.W.), and Grant No. 12-1-2-15-jch from the Innovative Platform Project of Qingdao (S.Z., Y.W.) in the People’s Republic of China., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Functional toll-like receptor 4 overexpression in papillary thyroid cancer by MAPK/ERK–induced ETS1 transcriptional activity

  • Peyret, Victoria
  • Nazar, Magalí
  • Martín, Mariano
  • Quintar, Amado A.
  • Fernandez, Elmer A.
  • Geysels, Romina C.
  • Fuziwara, Cesar S.
  • Montesinos, María M.
  • Maldonado, Cristina A.
  • Santisteban, Pilar
  • Kimura, Edna T.
  • Pellizas, Claudia G.
  • Nicola, Juan P.
  • Masini-Repiso, Ana M.
Emerging evidence suggests that unregulated Toll-like receptor (TLR) signaling promotes tumor survival signals, thus favoring tumor progression. Here, the mechanism underlying TLR4 overexpression in papillary thyroid carcinomas (PTC) mainly harboring the BRAFV600E mutation was studied. TLR4 was overexpressed in PTC compared with nonneoplastic thyroid tissue. Moreover, paired clinical specimens of primary PTC and its lymph node metastasis showed a significant upregulation of TLR4 levels in the metastatic tissues. In agreement, conditional BRAFV600E expression in normal rat thyroid cells and mouse thyroid tissue upregulated TLR4 expression levels. Furthermore, functional TLR4 expression was demonstrated in PTC cells by increased NF-κB transcriptional activity in response to the exogenous TLR4-agonist lipopolysaccharide. Of note, The Cancer Genome Atlas data analysis revealed that BRAFV600E-positive tumors with high TLR4 expression were associated with shorter disease-free survival. Transcriptomic data analysis indicated a positive correlation between TLR4 expression levels and MAPK/ERK signaling activation. Consistently, chemical blockade of MAPK/ERK signaling abrogated BRAFV600E-induced TLR4 expression. A detailed study of the TLR4 promoter revealed a critical MAPK/ERK–sensitive Ets-binding site involved in BRAFV600E responsiveness. Subsequent investigation revealed that the Ets-binding factor ETS1 is critical for BRAFV600E-induced MAPK/ERK signaling-dependent TLR4 gene expression. Together, these data indicate that functional TLR4 overexpression in PTCs is a consequence of thyroid tumor-oncogenic driver dysregulation of MAPK/ERK/ETS1 signaling., [Implications]: Considering the participation of aberrant NF-κB signaling activation in the promotion of thyroid tumor growth and the association of high TLR4 expression with more aggressive tumors, this study suggests a prooncogenic potential of TLR4 downstream signaling in thyroid tumorigenesis., This work was supported by fellowships and research grants from Agencia Nacional de Promocion Científica y Tecnologica (PICT-2008-0890 and PICT-2014-2564 to A.M. Masini-Repiso; PICT-2014-0726, PICT-2015-3839 and PICT-2015-3705 to J.P. Nicola), Consejo Nacional de Investigaciones Científicas y Tecnicas, Secretaría de Ciencia y Tecnología of Universidad Nacional de Cordoba, Latin American Thyroid Society and Thyroid Cancer Survivors' Association (to J.P. Nicola), Ministerio de Economía y Competitividad de España - Fondo Europeo de Desarrollo Regional (SAF2016-75531-R to P. Santisteban), and Fundacion Española contra el Cancer (GCB14142311CRES to P. Santisteban)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN

  • Ramírez-Moya, Julia
  • Wert-Lamas, León
  • Santisteban, Pilar
Recent studies have shown that miR-146b is the most upregulated microRNA in thyroid cancer and has a central role in cancer progression through mechanisms that remain largely unidentified. As phosphoinositide 3-kinase/protein kinase-B (PI3K/AKT) signaling is a fundamental oncogenic driver in many thyroid cancers, we explored a potential role for miR-146b and its target genes in PI3K/AKT activation. Among the predicted target genes of miR-146b, we found the tumor-suppressor phosphatase and tensin homolog (PTEN). Constitutive overexpression of miR-146b in thyroid epithelial cell lines significantly decreased PTEN mRNA and protein levels by direct binding to its 3'-UTR. This was accompanied by PI3K/AKT hyperactivation, leading to the exclusion of FOXO1 and p27 from the nucleus and a corresponding increase in cellular proliferation. Moreover, miR-146b overexpression led to protection from apoptosis and an increased migration and invasion potential, regulating genes involved in epithelial-mesenchymal transition. Notably, with the single exception of E-cadherin expression, all of these outcomes could be reversed by PTEN coexpression. Further analysis showed that miR-146b directly inhibits E-cadherin expression through binding to its 3'-UTR. Interestingly, miR-146b inhibition in human thyroid tumor xenografts, using a synthetic and clinically amenable molecule, blocked tumor growth when delivered intratumorally. Importantly, this inhibition increased PTEN protein levels. In conclusion, our data define a novel mechanism of PI3K/AKT hyperactivation and outline a regulatory role for miR-146b in suppressing PTEN expression, a frequent observation in thyroid cancer. Both events are related to a more aggressive tumoral phenotype. Targeting miR-146b therefore represents a promising therapeutic strategy for the treatment of this disease., This work was supported by grants SAF2013-44709-R and SAF2016-75531-R from the Ministerio de Economía y Competitividad (MINECO) of Spain, RD12/0036/0030 from Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER), and GCB14142311CRES from Fundación Española contra el Cancer. JR-M holds a FPU fellowship from Ministerio de Educación Cultura y Deporte. LW-L was funded by an FPI fellowship from MEC and is currently an investigator of the project PI14/01980 from ISCIII (Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Patient age–associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer

  • Shen, Xiaopei
  • Zhu, Guangwu
  • Liu, Rengyun
  • Viola, David
  • Elisei, Rossella
  • Puxeddu, Efisio
  • Fugazzola, Laura
  • Colombo, Carla
  • Jarzab, Barbara
  • Czarniecka, Agnieszka
  • Lam, Alfred K.
  • Mian, Caterina
  • Vianello, Federica
  • Yip, Linwah
  • Riesco-Eizaguirre, Garcilaso
  • Santisteban, Pilar
  • O’Neill, Christine J.
  • Sywak, Mark S.
  • Clifton-Bligh, Roderick
  • Bendlova, Bela
  • Sýkorová, Vlasta
  • Xing, Mingzhao
[Purpose]: For the past 65 years, patient age at diagnosis has been widely used as a major mortality risk factor in the risk stratification of papillary thyroid cancer (PTC), but whether this is generally applicable, particularly in patients with different BRAF genetic backgrounds, is unclear. The current study was designed to test whether patient age at diagnosis is a major mortality risk factor., [Patients and Methods]: We conducted a comparative study of the relationship between patient age at diagnosis and PTC-specific mortality with respect to BRAF status in 2,638 patients (623 men and 2,015 women) with a median age of 46 years (interquartile range, 35 to 58 years) at diagnosis and a median follow-up time of 58 months (interquartile range, 26 to 107 months). Eleven medical centers from six countries participated in this study., [Results]: There was a linear association between patient age and mortality in patients with BRAF V600E mutation, but not in patients with wild-type BRAF, in whom the mortality rate remained low and flat with increasing age. Kaplan-Meier survival curves rapidly declined with increasing age in patients with BRAF V600E mutation but did not decline in patients with wild-type BRAF, even beyond age 75 years. The association between mortality and age in patients with BRAF V600E was independent of clinicopathologic risk factors. Similar results were observed when only patients with the conventional variant of PTC were analyzed., [Conclusion]: The long-observed age-associated mortality risk in PTC is dependent on BRAF status; age is a strong, continuous, and independent mortality risk factor in patients with BRAF V600E mutation but not in patients with wild-type BRAF. These results question the conventional general use of patient age as a high-risk factor in PTC and call for differentiation between patients with BRAF V600E and wild-type BRAF when applying age to risk stratification and management of PTC., Supported by National Institutes of Health (NIH) Grants No. R01CA113507 and R01CA189224 (M.X.); Polish National Center of Research and Development MILESTONE Project Grant No. STRATEGMED2/267398/4/NCBR/2015 (Poland, A.C., B.J.); grants from Menzies Health Institute, Griffith University, Queensland Cancer Council and Queensland Smart State Fellowship (Australia; A.K.L.); Grants No. SAF2013-44709-R and SAF2016-75531-R (MINECO and FEDER), RD12/0036/0030, PI14/01980 (ISCIII), and GCB14142311CRES (AECC Foundation) (Spain; P.S. and G.R-E); Grants No. AZV 16-32665A and MH CZ-DRO (Institute of Endocrinology-EU, 00023761; Czech Republic; B.B., V.S.); grants from the New South Wales Cancer Institute (C.J.O.) and Cancer Council of New South Wales (Australia; R.C.-B.); NIH/National Institute on Aging Grant No. 5R03AG042334-02 (L.Y.); and grants from the Ministero della Istruzione Universitaria e Ricerca Scientifica, the Associazione Italiana per la Ricerca sul Cancro, the Istituto Toscano Tumori, and the Ministero della Salute (Italy; D.V., R.E.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Role of iodide metabolism in physiology and cancer

  • Vieja, Antonio de la
  • Santisteban, Pilar
Iodide (I-) metabolism is crucial for the synthesis of thyroid hormones (THs) in the thyroid and the subsequent action of these hormones in the organism. I- is principally transported by the sodium iodide symporter (NIS) and by the anion exchanger PENDRIN, and recent studies have demonstrated the direct participation of new transporters including anoctamin 1 (ANO1), cystic fibrosis transmembrane conductance regulator (CFTR) and sodium multivitamin transporter (SMVT). Several of these transporters have been found expressed in various tissues, implicating them in I- recycling. New research supports the exciting idea that I- participates as a protective antioxidant and can be oxidized to hypoiodite, a potent oxidant involved in the host defense against microorganisms. This was possibly the original role of I- in biological systems, before the appearance of TH in evolution. I- per se participates in its own regulation, and new evidence indicates that it may be antineoplastic, anti-proliferative and cytotoxic in human cancer. Alterations in the expression of I- transporters are associated with tumor development in a cancer-type-dependent manner and, accordingly, NIS, CFTR and ANO1 have been proposed as tumor markers. Radioactive iodide has been the mainstay adjuvant treatment for thyroid cancer for the last seven decades by virtue of its active transport by NIS. The rapid advancement of techniques that detect radioisotopes, in particular I-, has made NIS a preferred target-specific theranostic agent., This work was supported by grants from the Ministerio de Economía y Competitividad and European Regional Development Fund (FEDER) SAF2015-69964-R (to A D l V) and SAF2016-75531-R (to P S), grant PI12-01201 from the Instituto de Salud Carlos III (to A D l V), grant GCB14142311CRES from Fundación Española Contra el Cancer (to P S), Programa de Biomedicina Comunidad de Madrid Grant B2017/BMD-3724 Tironet2 and CiberOnc from the Instituto de Salud Carlos III (to A D l V and P S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

TAZ/WWTR1 mediates the pulmonary effects of NKX2-1 mutations in brain-lung-thyroid syndrome

  • Moya, Christian M.
  • Zaballos, Miguel A.
  • Garzón, Lucía
  • Luna, Carmen
  • Simón, Rogelio
  • Yaffe, Michael B.
  • Gallego, Elena
  • Santisteban, Pilar
  • Moreno, José C.
[Context]: Identification of a frameshift heterozygous mutation in the transcription factor NKX2-1 in a patient with brain-lung-thyroid syndrome (BLTS) and life-threatening lung emphysema., [Objective]: To study the genetic defect that causes this complex phenotype and dissect the molecular mechanism underlying this syndrome through functional analysis., [Methods]: Mutational study by DNA sequencing, generation of expression vectors, site-directed mutagenesis, protein–DNA-binding assays, luciferase reporter gene assays, confocal microscopy, coimmunoprecipitation, and bioinformatics analysis., [Results]: We identified a mutation [p.(Val75Glyfs*334)] in the amino-terminal domain of the NKX2-1 gene, which was functionally compared with a previously identified mutation [p.(Ala276Argfs*75)] in the carboxy-terminal domain in other patients with BLTS but without signs of respiratory distress. Both mutations showed similar protein expression profiles, subcellular localization, and deleterious effects on thyroid-, brain-, and lung-specific promoter activity. Coexpression of the coactivator TAZ/WWTR1 (transcriptional coactivator with PDZ-binding motif/WW domain-containing transcription regulator protein 1) restored the transactivation properties of p.(Ala276Argfs*75) but not p.(Val75Glyfs*334) NKX2-1 on a lung-specific promoter, although both NKX2-1 mutants could interact equally with TAZ/WWTR1. The retention of residual transcriptional activity in the carboxy-terminal mutant, which was absent in the amino-terminal mutant, allowed the functional rescue by TAZ/WWTR1., [Conclusions]: Our results support a mechanistic model involving TAZ/WWTR1 in the development of human congenital emphysema, suggesting that this protein could be a transcriptional modifier of the lung phenotype in BLTS., This work was supported by funding from the Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (grants PI1002160 and PI16/00830 to J.C.M.) and Ministerio de Economia y Competitividad of Spain, Fondo Europeo de Desarrollo Regional (grants SAF2013-44709R and SAF2016-75531R to P.S.). M.A.Z. and P.S. were supported by CIBERONC. C.M.M. was supported by a postdoctoral fellowship from the Research Program of the European Society for Pediatric Endocrinology., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

A novel role for the Hippo pathway mediator TAZ in thyroid differentiation

  • Fernández-Méndez, Celia
  • Santisteban, Pilar
Resumen del trabajo presentado al 1st PhD Research Symposium in Health Sciences and Biomedicine, celebrado en la Universidad Autónoma de Madrid el 18 de mayo de 2018., SAF2016-75531-R, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Emerging genes and pathways in thyroid differentiation and tumorigenesis

  • Santisteban, Pilar
Trabajo presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., Thyroid cancer remains the most common endocrine malignancy worldwide and its incidence and mortality has increased steadily over the last four decades., Grants SAF2016-75531-R from MINECO, Spain (FEDER); B2017/BMD-3724 from CAM and GCB14142311CRES from AECC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Interplay between TGFβ and the Hippo mediator TAZ leads to Sodium-iodide symporter inhibition

  • Fernández-Méndez, Celia
  • Santisteban, Pilar
Resumen del póster presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., TAZ is a well-known coactivator downstream of the Hippo signaling pathway. Together with its paralogous YAP and the transcription factors of the TEAD family, TAZ plays a key role in the regulation of differentiation, among other cellular processes. Little is known about the involvement of this signaling pathway in the function of the thyroid gland, although TAZ has been described as a coactivator of Pax8 on the thyroglobulin promoter. Pax8 has a predominant role in thyroid differentiation by regulating the transcription of many crucial genes, such as sodium-iodide symporter (NIS). The aim of this work was to study the role of the Hippo pathway, and particularly its mediator TAZ, in NIS expression, and hence in thyroid differentiation. By western blot and immunofluorescence, we show TAZ nuclear expression is promoted by TGFβ signalling through its downstream mediator p38. We demonstrated that nuclear TAZ exerts a marked role as NIS repressor, decreasing its expression levels, affecting its presence in the celular membrane and thus impairing iodide uptake. By chromatin immunoprecipitation (ChIP) and luciferase reporter assays, we demonstrated that TAZ strongly suppresses Pax8 activation of the NIS promoter by decreasing its binding to the NIS Upstream Enhancer (NUE). In fact, the absence of TAZ directly increases Pax8 nuclear levels. RNAi assays of other Hippo effectors were performed in order to check their participation in this process. Although YAP and TEAD1 could have additive effects, TAZ seems to be the main requirement for NIS downregulation. TGFβ role in thyroid differentiation is well establish, however here we describe a novel crosstalk with the Hippo Pathway and its mediator TAZ, remarkably involved in the control of the sodium iodide symporter expression., SAF2016-75531-R, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Antitumor activity of the ERK inhibitor DEL22379 against BRAF-like cells in thyroid cancer

  • Acuña-Ruiz, Adrián
  • Zaballos, Miguel A.
  • Riesco-Eizaguirre, Garcilaso
  • Crespo, Piero
  • Santisteban, Pilar
Resumen del póster presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., Thyroid cancer is the most prevalent human carcinoma of endocrine origin and its incidence is continuously increasing. Around 80% of all the somatic mutations are accumulated in only five driver genes (BRAF, H/N/K-RAS and RET) which converge in the hyperactivation of the MAPK signalling pathway. Given the central role of this pathway in thyroid tumorigenesis, thyroid cancer research is focused on the identification of new drugs that inhibit the different kinases of the pathway. DEL22379 is an inhibitor of ERK dimerization previously characterized in melanoma and colorectal cancer-derived cell lines as a new approach to partially inhibit ERK activation. It has been reported that ERK dimerization contributes to the activation of ERK cytoplasmic effectors, such as RSK, and enhances malignant cell features. Our objective was to analyse the antitumor effect of the inhibitor of ERK dimerization DEL22379 as a possible therapeutic compound in thyroid cancer. In vitro assays were made with different thyroid cancer cell lines with mutations in BRAF, H/N/K-RAS or RET. To evaluate cell proliferation, migration and invasion; we have used cell cycle, wound healing and matrigel invasion assays, respectively. We also have developed an orthotopic mouse model of anaplastic thyroid cancer by the generation of the 8505c-luc cell line. In vivo tumour progression was monitored by measuring luciferase activity. Treatment with DEL22379 impairs ERK dimers formation in BRAF-like thyroid cells whereas Ras-like cells were unaffected. Unlike melanoma, phosphorylated ERK levels were substantially reduced after treatment with the inhibitor. Inhibition of ERK dimerization and phosphorylation correlated with diminished RSK phosphorylation. We also observed a decrease in cell proliferation, migration and invasion in the anaplastic thyroid cell lines 8505c and OCUT2. DEL22379 treatment significantly reduced tumour growth and formation of lung metastases in an orthotopic mouse model. We propose DEL22379 as a new effective molecule for the inhibition of MAPK signalling and the reduction of cell malignant behaviour, tumour growth and metastasis in vivo, specifically in BRAF-like thyroid tumours. It promises to be another step forward in the achievement to cure thyroid cancer., This work was supported by grants SAF2016-75531-R from Ministerio de Economía y Empresa (MINECO), Spain and PI14/01980 from ISCIII, Spain (FEDER) and GCB14142311CRES from Asociación Española contra el Cancer (AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Role of the IQGAP1 scaffold protein in thyroid cancer

  • Carrasco-López, Carlos
  • Zaballos, Miguel A.
  • Santisteban, Pilar
Resumen del póster presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., The IQGAP family of scaffold proteins comprises three members which have been described to interact with numerous proteins in several biological processes and participate in the signaling cascade of multiple pathways. Among these proteins IQGAP1 has been the most deeply studied, having characterized its function as a scaffold protein in the MAPK pathway and its interaction with actin leading to regulation of the cytoskeleton. Because of these functions it has been studied in multiple malignancies, where it has been assigned a tumorigenic effect. We have studied IQGAP1 expression using different stablished cell lines of human thyroid carcinomas. Our results indicate that these carcinoma cell lines have variable levels of IQGAP1 but in general these levels are higher when compared to the normal thyroid cell line control. The results obtained are in agreement with the TCGA and Oncomine databases. Using IQGAP1 silenced cell lines we tried to elucidate how this protein was affecting tumor hallmarks such as proliferation, invasion, cell migration and epithelial mesenchymal transition. The effects of silencing IQGAP1 were different depending on the cell line and the oncogenic signature. While in some of them silencing produced an increase in the migration rate of the cells, others had the opposite behavior. We also found these differences when studying EMT markers such as E-cadherin and N-cadherin. Furthermore, cell viability was unaffected by IQGAP1 silencing and consequently the size of the primary tumor was not altered when cells were xenografted in a chicken embryo model. Importantly IQGAP1 silencing greatly decreased the ability of the tumor cells to intravasate and metastasize to distant organs such as lungs and brain. Further studies will focus on trying to discover the underlying mechanisms responsible for the differences observed between cell lines. Our results indicate a role forIQGAP1 in thyroid tumorigenesis and underscore the importance of defining the oncogenic signature and particularities of a given tumor type in order to design effective therapeutic strategies., This work was supported by grants SAF2016-75531-R from MINECO, Spain and PI14/01980 from ISCIII, Spain (FEDER); B2017/BMD-3724 from CAM and GCB14142311CRES from AECC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer

  • Zaballos, Miguel A.
  • Acuña-Ruiz, Adrián
  • Morante, Marta
  • Crespo, Piero
  • Santisteban, Pilar
Thyroid cancer is mostly an ERK-driven carcinoma, as up to 70% of thyroid carcinomas are caused by mutations that activate the RAS/ERK mitogenic signaling pathway. The incidence of thyroid cancer has been steadily increasing for the last four decades; yet, there is still no effective treatment for advanced thyroid carcinomas. Current research efforts are focused on impairing ERK signaling with small-molecule inhibitors, mainly at the level of BRAF and MEK. However, despite initial promising results in animal models, the clinical success of these inhibitors has been limited by the emergence of tumor resistance and relapse. The RAS/ERK pathway is an extremely complex signaling cascade with multiple points of control, offering many potential therapeutic targets: from the modulatory proteins regulating the activation state of RAS proteins to the scaffolding proteins of the pathway that provide spatial specificity to the signals, and finally, the negative feedbacks and phosphatases responsible for inactivating the pathway. The aim of this review is to give an overview of the biology of RAS/ERK regulators in human cancer highlighting relevant information on thyroid cancer and future areas of research., The Santisteban and Crespo Laboratories are supported jointly by grants from Asociación Española Contra el Cancer (AECC; GCB141423113) and CIBERONC from the Instituto de Salud Carlos III (ISCIII). In addition, the authors acknowledge the following funding support: SAF2016-75531-R (MINECO/FEDER, UE); B2017/BMD-3724 Tironet2 (Comunidad de Madrid) and RTICC from ISCIII (RD/12/0036/0030) (granted to P S); and SAF-2015 63638R (MINECO/FEDER, UE) and RTICC (RD/12/0036/0033) (granted to P C).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness

  • Ramírez-Moya, Julia
  • Wert-Lamas, León
  • Riesco-Eizaguirre, Garcilaso
  • Santisteban, Pilar
The global downregulation of microRNAs (miRNAs) is emerging as a common hallmark of cancer. However, the mechanisms underlying this phenomenon are not well known. We identified that the oncogenic miR-146b-5p attenuates miRNA biosynthesis by targeting DICER1 and reducing its expression. DICER1 overexpression inhibited all the miR-146b-induced aggressive phenotypes in thyroid cells. Systemic injection of an anti-miR-146b in mice with orthotopic thyroid tumors suppressed tumor growth and recovered DICER1 levels. Notably, DICER1 downregulation promoted proliferation, migration, invasion, and epithelial-mesenchymal transition through miRNA downregulation. Our analysis of The Cancer Genome Atlas revealed a general decrease in DICER1 expression in thyroid cancer that was associated with a worse clinical outcome. Administration of the small-molecule enoxacin to promote DICER1 complex activity reduced tumor aggressiveness both in vitro and in vivo. Overall, our data confirm DICER1 as a tumor suppressor and show that oncogenic miR-146b contributes to its downregulation. Moreover, our results highlight a potential therapeutic application of RNA-based therapies including miRNA inhibitors and restoration of the biogenesis machinery, which may provide treatments for thyroid and other cancers., This work was supported by grants SAF2016-75531-R from MINECO, Spain and PI14/01980 from ISCIII, Spain (FEDER)); B2017/BMD-3724 from CAM and GCB14142311CRES from F-AECC. JR-M holds a FPU fellowship from MECD (Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MiRNA-directed regulation of the main signaling pathways in thyroid cancer

  • Ramírez-Moya, Julia
  • Santisteban, Pilar
© 2019 Ramírez-Moya and Santisteban., In the last two decades, great strides have been made in the study of microRNAs in development and in diseases such as cancer, as reflected in the exponential increase in the number of reviews on this topic including those on undifferentiated and well-differentiated thyroid cancer. Nevertheless, few reviews have focused on understanding the functional significance of the most up- or down-regulated miRNAs in thyroid cancer for the main signaling pathways hyperactivated in this tumor type. The aim of this review is to discuss the major miRNAs targeting proteins of the MAPK, PI3K, and TGFβ pathways, to define their mechanisms of action through the 3′UTR regions of their target genes, and to describe how they affect thyroid tumorigenesis through their actions on cell proliferation, migration, and invasion. Given the importance of miRNAs in cancer as diagnostic, prognostic and therapeutic candidates, a better understanding of this cross-talk might shed new light on the biomedical treatment of thyroid cancer., We acknowledge the support of grants SAF2016-75531-R (MINECO/FEDER, UE); Asociación Española Contra el Cancer (AECC; GCB141423113); CIBERONC from the Instituto de Salud Carlos III (ISCIII) and B2017/BMD-3724 Tironet2 (Comunidad de Madrid). JR-M, holds a FPU fellowship from Spanish Ministry of Education.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Regulation of Foxe1 by Thyrotropin and Transforming Growth Factor Beta Depends on the Interplay between Thyroid-Specific, CREB and SMAD Transcription Factors

  • López-Márquez, Arístides
  • Fernández-Méndez, Celia
  • Recacha, Pablo
  • Santisteban, Pilar
[Background]: Thyroid follicular cells are characterized by the expression of a specific set of genes necessary for the synthesis and secretion of thyroid hormones, which are in turn regulated by the transcription factors Nkx2-1, Pax8, and Foxe1. Thyroid differentiation is finely tuned by the balance between positive regulatory signals, including thyrotropin (TSH), and by negative regulatory signals, such as transforming growth factor beta (TGF-β), which counteracts the action of TSH. A role for Foxe1 as a mediator of hormonal and growth-factor control of thyroid differentiation has been previously suggested. Therefore, the aim of this work was to study the mechanisms governing Foxe1 expression to define the ligands and signals that regulate one of the important factors in thyroid differentiation., [Methods]: Expression of Foxe1 was evaluated in rat PCCl3 thyroid follicular cells under different treatments. The mouse Foxe1 promoter was cloned, and site-directed mutagenesis was undertaken to study its transcriptional regulation and to identify response elements. Protein/DNA binding assays were performed to evaluate the binding of different transcription factors, and gene-silencing approaches were used to elucidate their functional roles., [Results]: In silico analysis of the Foxe1 promoter identified binding sites for Nkx2-1, Pax8, Foxe1, and Smad proteins, as well as cAMP-response element (CRE) sites. It was found that both CRE-binding protein and CRE modulator were necessary for the TSH-mediated induction of Foxe1 expression via the cAMP/PKA signaling pathway. Moreover, transcription of Foxe1 was regulated by Nkx2-1 and Pax8 and by itself, suggesting an autoregulatory mechanism of activation and an important role for thyroid transcription factors. Finally, TGF-β, through Smad proteins, inhibited the TSH-induced Foxe1 expression., [Conclusions]: This study shows that Foxe1 is the final target of TSH/cAMP and TGF-β regulation that mediates expression of thyroid differentiation genes, and provides evidence of an interplay between CRE-binding proteins, thyroid transcription factors, and Smad proteins in its regulation. Thus, Foxe1 plays an important role in the complex transcriptional network that regulates thyroid follicular cell differentiation., This work was supported by grants SAF2016-75531-R from the Ministerio de Economía, Industria y Competitividad (Spain), Fondo Europeo de Desarrollo Regional (FEDER), B2017/BMD-3724 TIRONET2-CM from the Comunidad de Madrid, and GCB14142311CRES from Fundación Española contra el Cáncer (AECC) to P.S. A.L.-M. and C.F.-M. hold an FPI fellowship from Universidad Autónoma de Madrid.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity

  • Ramírez-Moya, Julia
  • Baker, Allison R.
  • Slack, Frank J.
  • Santisteban, Pilar
Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine in double-stranded RNA. A-to-I editing of RNA is a widespread posttranscriptional process that has recently emerged as an important mechanism in cancer biology. A-to-I editing levels are high in several human cancers, including thyroid cancer, but ADAR1 editase-dependent mechanisms governing thyroid cancer progression are unexplored. To address the importance of RNA A-to-I editing in thyroid cancer, we examined the role of ADAR1. Loss-of-function analysis showed that ADAR1 suppression profoundly repressed proliferation, invasion, and migration in thyroid tumor cell models. These observations were validated in an in vivo xenograft model, which showed that ADAR1-silenced cells had a diminished ability to form tumors. RNA editing of miRNAs has the potential to markedly alter target recognition. According to TCGA data, the tumor suppressor miR-200b is overedited in thyroid tumors, and its levels of editing correlate with a worse progression-free survival and disease stage. We confirmed miR-200b overediting in thyroid tumors and we showed that edited miR-200b has weakened activity against its target gene ZEB1 in thyroid cancer cells, likely explaining the reduced aggressiveness of ADAR1-silenced cells. We also found that RAS, but not BRAF, modulates ADAR1 levels, an effect mediated predominantly by PI3K and in part by MAPK. Lastly, pharmacological inhibition of ADAR1 activity with the editing inhibitor 8-azaadenosine reduced cancer cell aggressiveness. Overall, our data implicate ADAR1-mediated A-to-I editing as an important pathway in thyroid cancer progression, and highlight RNA editing as a potential therapeutic target in thyroid cancer., This work was supported by grants SAF2016-75531-R from Ministerio de Ciencia e Innovación (MICIN), Spain, Fondo Europeo de Desarrollo Regional FEDER, B2017/BMD-3724 from Comunidad de Madrid, and GCB14142311CRES from Fundación Española contra el Cáncer (AECC) (To PS), and by the Ludwig Center at Harvard (To FJS). JR-M hold a FPU fellowship from MECD (Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A novel role for the tumor suppressor gene ITF2 in tumorigenesis and chemotherapy response

  • Pernía, Olga
  • Sastre-Perona, Ana
  • Rodriguez-Antolín, Carlos
  • García-Guede, Alvaro
  • Palomares, María
  • Rosas, Rocio
  • Sanchez-Cabrero, Darío
  • Cruz, Patricia
  • Rodríguez, Carmen
  • Diestro, M. Dolores
  • Martín-Arenas, Rubén
  • Pulido, Veronica
  • Santisteban, Pilar
  • Castro Carpeño, Javier de
  • Vera Puente, Olga
  • Ibáñez de Cáceres, Inmaculada
This article belongs to the Special Issue Non-small Cell Lung Cancer—Tumor Biology., Despite often leading to platinum resistance, platinum-based chemotherapy continues to be the standard treatment for many epithelial tumors. In this study we analyzed and validated the cytogenetic alterations that arise after treatment in four lung and ovarian paired cisplatin-sensitive/resistant cell lines by 1-million microarray-based comparative genomic hybridization (array-CGH) and qRT-PCR methodologies. RNA-sequencing, functional transfection assays, and gene-pathway activity analysis were used to identify genes with a potential role in the development of this malignancy. The results were further explored in 55 lung and ovarian primary tumors and control samples, and in two extensive in silico databases. Long-term cell exposure to platinum induces the frequent deletion of ITF2 gene. Its expression re-sensitized tumor cells to platinum and recovered the levels of Wnt/β-catenin transcriptional activity. ITF2 expression was also frequently downregulated in epithelial tumors, predicting a worse overall survival. We also identified an inverse correlation between ITF2 and HOXD9 expression, revealing that Non-small cell lung cancer (NSCLC) patients with lower expression of HOXD9 had a better overall survival rate. We defined the implication of ITF2 as a molecular mechanism behind the development of cisplatin resistance probably through the activation of the Wnt-signaling pathway. This data highlights the possible role of ITF2 and HOXD9 as novel therapeutic targets for platinum resistant tumors., This research was funded by the Fondo de Investigación Sanitaria-Instituto de Salud Carlos III, PI15/00186 and PI18/00050, CP19/00063, and CM19/00100 for HR and by MINECO, RTC-2016-5314-1 to I.I.C; by the MINECO, SAF2016-75531-R, by the CAM B2017/BMD-3724 and by the AECC GCB14142311CRES to P.S; and the European Regional Development Fund/European Social Fund FIS (FEDER/FSE, Una Manera de Hacer Europa)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma

  • Kim, Kyeong J.
  • Kim, Sin G.
  • Tan, Jie
  • Shen, Xiaopei
  • Viola, David
  • Elisei, Rossella
  • Puxeddu, Efisio
  • Fugazzola, Laura
  • Colombo, Carla
  • Jarzab, Barbara
  • Czarniecka, Agnieszka
  • Lam, Alfred K.
  • Mian, Caterina
  • Vianello, Federica
  • Yip, Linwah
  • Riesco-Eizaguirre, Garcilaso
  • Santisteban, Pilar
  • O'Neill, Christine J.
  • Sywak, Mark S.
  • Clifton-Bligh, Roderick
  • Bendlova, Bela
  • Sýkorová, Vlasta
  • Sýkorová, Vlasta
[Introduction]: Conservative active surveillance has been proposed for low-risk papillary thyroid microcarcinoma (PTMC), defined as ≤1.0 cm and lacking clinical aggressive features, but controversy exists with accepting it as not all such PTMCs are uniformly destined for benign prognosis. This study investigated whether BRAF V600E status could further risk stratify PTMC, particularly low-risk PTMC, and can thus help with more accurate case selection for conservative management., [Methods]: This international multicenter study included 743 patients treated with total thyroidectomy for PTMC (584 women and 159 men), with a median age of 49 years (interquartile range [IQR], 39–59 years) and a median follow-up time of 53 months (IQR, 25–93 months)., [Results]: On overall analyses of all PTMCs, tumour recurrences were 6.4% (32/502) versus 10.8% (26/241) in BRAF mutation-negative versus BRAF mutation-positive patients (P = 0.041), with a hazard ratio (HR) of 2.44 (95% CI (confidence interval), 1.15–5.20) after multivariate adjustment for confounding clinical factors. On the analyses of low-risk PTMC, recurrences were 1.3% (5/383) versus 4.3% (6/139) in BRAF mutation-negative versus BRAF mutation-positive patients, with an HR of 6.65 (95% CI, 1.80–24.65) after adjustment for confounding clinical factors. BRAF mutation was associated with a significant decline in the Kaplan–Meier recurrence-free survival curve in low-risk PTMC., [Conclusions]: BRAF V600E differentiates the recurrence risk of PTMC, particularly low-risk PTMC. Given the robust negative predictive value, conservative active surveillance of BRAF mutation-negative low-risk PTMC is reasonable whereas the increased recurrence risk and other well-known adverse effects of BRAF V600E make the feasibility of long-term conservative surveillance uncertain for BRAF mutation-positive PTMC., This study was supported partly by US National Institutes of Health (NIH) Grant Nos. R01CA215142 and R01CA189224 (M.X.) and by the following additional funding at the individual participating centres: Polish National Center of Research and Development MILESTONE (Molecular Diagnostics and Imaging in Individualized Therapy for Breast, Thyroid and Prostate Cancer) Project Grant No. STRATEGMED2/267398/4/NCBR/2015 (A.C., B.J.); grants from the Menzies Health Institute, Griffith University, Queensland Cancer Council, and Queensland Smart State Fellowship in Australia (A.K.L.); Ministry of Economy and Competitiveness (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) Grant No. SAF2016-75531-R, Instituto de Salud Carlos III Grant No. PI14/01980, Asociación Española Contra el Cáncer Foundation Grant No. GCB14142311CRES, and TIRONET2-CM Grant No. B2017/BMD-3724 TIRONET2-CM in Spain (P.S., G.R.-E.); Institute of Endocrinology Grant Nos. AZV 16-32665A and MH CZ-DRO 00023761 in the Czech Republic (B.B., V.S.); grants from the New South Wales Cancer Institute (C.J.O.) and Cancer Council of New South Wales (R.C.-B.) in Australia; National Institute on Aging, NIH, Grant No. 5R03AG042334-02 (L.Y.); grants from the Ministero della Istruzione Universitaria e Ricerca Scientifica, the Associazione Italiana per la Ricerca sul Cancro, the Istituto Toscano Tumori, and the Ministero della Salute in Italy (D.V. and R.E.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

FOXE1 regulates migration and invasion in thyroid cancer cells and targets ZEB1

  • Morillo-Bernal, Jesús
  • Fernández, Lara P.
  • Santisteban, Pilar
FOXE1 is a thyroid-specific transcription factor essential for thyroid gland development and maintenance of the differentiated state. Interestingly, a strong association has been recently described between FOXE1 expression and susceptibility to thyroid cancer, but little is known about the mechanisms underlying FOXE1-induced thyroid tumorigenesis. Here, we used a panel of human thyroid cancer-derived cell lines covering the spectrum of thyroid cancer phenotypes to examine FOXE1 expression and to test for correlations between FOXE1 expression, the allele frequency of two SNPs and a length polymorphism in or near the FOXE1 locus associated with cancer susceptibility, and the migration ability of thyroid cancer cell lines. Results showed that FOXE1 expression correlated with differentiation status according to histological sub-type, but not with SNP genotype or cell migration ability. However, loss-and-gain-of-function experiments revealed that FOXE1 modulates cell migration, suggesting a role in epithelial-to-mesenchymal transition (EMT). Our previous genome-wide expression analysis identified Zeb1, a major EMT inducer, as a putative Foxe1 target gene. Indeed, gene silencing of FOXE1 decreased ZEB1 expression, whereas its overexpression increased ZEB1 transcriptional activity. FOXE1 was found to directly interact with the ZEB1 promoter. Lastly, ZEB1 silencing decreased the ability of thyroid tumoral cells to migrate and invade, pointing to its importance in thyroid tumor mestastases. In conclusion, we have identified ZEB1 as a bona fide target of FOXE1 in thyroid cancer cells, which provides new insights into the role of FOXE1 in regulating cell migration and invasion in thyroid cancer., This work was supported by grants SAF2016-75531-R from Ministerio de Ciencia, Innovación y Universidades (MICIU), Spain, Fondo Europeo de Desarrollo Regional FEDER, B2017/BMD-3724 from Comunidad de Madrid, and GCB14142311CRES from Fundación Española Contra el Cáncer (AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gene network transitions in embryos depend upon interactions between a pioneer transcription factor and core histones

  • Iwafuchi, Makiko
  • Cuesta Suárez, Isabel
  • Donahue, Greg
  • Takenaka, Naomi
  • Osipovich, Anna B.
  • Magnuson, Mark A.
  • Roder, Heinrich
  • Seeholzer, Steven H.
  • Santisteban, Pilar
  • Zaret, Kenneth S.
Gene network transitions in embryos and other fate-changing contexts involve combinations of transcription factors. A subset of fate-changing transcription factors act as pioneers; they scan and target nucleosomal DNA and initiate cooperative events that can open the local chromatin. However, a gap has remained in understanding how molecular interactions with the nucleosome contribute to the chromatin-opening phenomenon. Here we identified a short α-helical region, conserved among FOXA pioneer factors, that interacts with core histones and contributes to chromatin opening in vitro. The same domain is involved in chromatin opening in early mouse embryos for normal development. Thus, local opening of chromatin by interactions between pioneer factors and core histones promotes genetic programming., M.I. was supported by postdoctoral fellowships from Japan Society for the Promotion of Science Foundation (H26-683), Naito Foundation (RYU10000032), Astellas Foundation for Research on Metabolic Disorders (K0076) and Uehara Memorial Foundation (H24-20124). P.S. was supported by grant nos. SAF2016-75531-R (MICINN/FEDER, UE) and B2017/BMD-3724 (Comunidad de Madrid). The research was supported by NIH grant no. GM36477 to K.S.Z., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impaired gene expression due to iodine excess in the development and differentiation of endoderm and thyroid is associated with epigenetic changes

  • Serrano-Nascimento, Caroline
  • Morillo-Bernal, Jesús
  • Rosa-Ribeiro, Rafaela
  • Nunes, Maria Tereza
  • Santisteban, Pilar
[Background]: Thyroid hormone (TH) synthesis is essential for the control of development, growth, and metabolism in vertebrates and depends on a sufficient dietary iodine intake. Importantly, both iodine deficiency and iodine excess (IE) impair TH synthesis, causing serious health problems especially during fetal/neonatal development. While it is known that IE disrupts thyroid function by inhibiting thyroid gene expression, its effects on thyroid development are less clear. Accordingly, this study sought to investigate the effects of IE during the embryonic development/differentiation of endoderm and the thyroid gland., [Methods]: We used the murine embryonic stem (ES) cell model of in vitro directed differentiation to assess the impact of IE on the generation of endoderm and thyroid cells. Additionally, we subjected endoderm and thyroid explants obtained during early gestation to IE and evaluated gene and protein expression of endodermal markers in both models., [Results]: ES cells were successfully differentiated into endoderm cells and, subsequently, into thyrocytes expressing the specific thyroid markers Tshr, Slc5a5, Tpo, and Tg. IE exposure decreased the messenger RNA (mRNA) levels of the main endoderm markers Afp, Crcx4, Foxa1, Foxa2, and Sox17 in both ES cell-derived endoderm cells and embryonic explants. Interestingly, IE also decreased the expression of the main thyroid markers in ES cell-derived thyrocytes and thyroid explants. Finally, we demonstrate that DNA methyltransferase expression was increased by exposure to IE, and this was accompanied by hypermethylation and hypoacetylation of histone H3, pointing to an association between the gene repression triggered by IE and the observed epigenetic changes., [Conclusions]: These data establish that IE treatment is deleterious for embryonic endoderm and thyroid gene expression., This study was supported by grants from Fundaçao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) to C.S.-N. (12/24391-6, 15/16695-3, 16/18517-8) and to M.T.N. (13/05629-4); and grants from Ministerio de Economia, Industria y Competitividad (Spain; MINECO) (SAF2016-75531-R) and from Comunidad Madrid (Spain; B2017/BMD-3724 TIRONET CM2) to P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RAS Subcellular Localization Inversely Regulates Thyroid Tumor Growth and Dissemination

  • García-Ibáñez, Yaiza
  • Riesco-Eizaguirre, Garcilaso
  • Santisteban, Pilar
  • Casar, Berta
  • Crespo, Piero
© 2020 by the authors., RAS mutations are the second most common genetic alteration in thyroid tumors. However, the extent to which they are associated with the most aggressive phenotypes is still controversial. Regarding their malignancy, the majority of RAS mutant tumors are classified as undetermined, which complicates their clinical management and can lead to undesired under- or overtreatment. Using the chick embryo spontaneous metastasis model, we herein demonstrate that the aggressiveness of HRAS-transformed thyroid cells, as determined by the ability to extravasate and metastasize at distant organs, is orchestrated by HRAS subcellular localization. Remarkably, aggressiveness inversely correlates with tumor size. In this respect, we also show that RAS site-specific capacity to regulate tumor growth and dissemination is dependent on VEGF-B secretion. Furthermore, we have identified the acyl protein thioesterase APT-1 as a determinant of thyroid tumor growth versus dissemination. We show that alterations in APT-1 expression levels can dramatically affect the behavior of thyroid tumors, based on its role as a regulator of HRAS sublocalization at distinct plasma membrane microdomains. In agreement, APT-1 emerges in thyroid cancer clinical samples as a prognostic factor. As such, APT-1 levels could serve as a biomarker that could help in the stratification of HRAS mutant thyroid tumors based on their aggressiveness., PC lab is supported by grant RTI2018-096658B-100 from the Spanish Ministry of Science (MICIU/AEI/FEDER, UE). Santisteban, Riesco and Crespo Laboratories are supported jointly by grants from Asociación Española Contra el Cancer (AECC; GCB141423113) and CIBERONC from the Instituto de Salud Carlos III (ISCIII). PS acknowledges support from: SAF2016-75531-R (MINECO/FEDER, UE); B2017/BMD-3724 Tironet2 (Comunidad de Madrid) and PID2019-105303RB-I00/AEI/10.13039/501100011033 from Ministerio de Ciencia e Innovación (MICIN). B.C is funded by Retos Jóvenes Investigadores grant SAF2015-73364-JIN (MICIU/AEI/FEDER, UE), a PIE grant from Consejo Superior de Investigaciones Científicas (CSIC)- MICIU and the Ramón y Cajal Research Program (MICIU, RYC2018-024004-I).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Critical balance between PAX8 and the hippo mediator TAZ Determines sodium/Iodide symporter expression and function

  • Fernández-Méndez, Celia
  • Santisteban, Pilar
[Background[: The Hippo pathway has a fundamental role in tissue homeostasis, but little is known about how this signaling cascade is controlled in the thyroid. PAX8 is an essential driver of thyroid differentiation and is involved in the control of genes crucial for thyroid hormone biosynthesis, including the sodium/iodide symporter (NIS; SLC5A5). A role for the Hippo mediator transcriptional coactivator with PDZ-binding motif (TAZ) as a coactivator of PAX8 to promote thyroglobulin expression has been previously described. Here, we studied the role of TAZ on thyroid differentiation focusing on PAX8-mediated Slc5a5 transcription. [Methods]: Gene silencing and overexpression assays were performed in rat PCCl3 thyroid follicular cells (TFCs) to determine the role of TAZ in the regulation of Slc5a5. Transcriptional activity of the Hippo mediators was investigated by chromatin immunoprecipitation and promoter-reporter gene activity. Hippo component levels and location were analyzed in PCCl3 cells and in mouse thyroid under different treatment conditions., [Results]: By suppressing the expression of PAX8 and its binding to the Slc5a5 upstream enhancer, TAZ inhibits Slc5a5 expression, impairing NIS membrane location and activity. Other Hippo effectors such as YAP1 and TEAD1 were not required for the repressor effect of TAZ. We also found an interplay between the Hippo, thyrotropin (TSH), and transforming growth factor β1 (TGFβ) pathways in TFCs. TSH via cyclic adenosine monophosphate activated Hippo signaling pathway and, consequently, TAZ was excluded from the nucleus. We confirmed this in hypothyroid mice, characterized by elevated TSH serum levels, which showed downregulated activation of Hippo signaling in thyroid. Conversely, TAZ nuclear retention was promoted by TGFβ, a potent NIS repressor, and TAZ silencing markedly relieved the TGFβ-induced inhibition of the symporter., [Conclusions]: We demonstrate that the effects of TAZ are promoter specific, as it functions as a corepressor of PAX8 to modulate Slc5a5 expression in TFCs. Overall, our data place TAZ as an integrator of the different signaling pathways that control NIS expression, pointing to a role for TAZ in thyroid differentiation and identifying the Hippo pathway as a relevant target to recover NIS levels in thyroid cancer cells., This work was supported by grants SAF2016-75531-R, Fondo Europeo de Desarrollo Regional, and PID2019- 105303RB-I00/AEI/10.13039/501100011033 from the Ministerio de Ciencia e Innovacio´n (MICIN), Spain; and by grant S2017/BMD-3724 from Comunidad de Madrid. C.F.-M. holds an FPI fellowship from Universidad Auto´noma de Madrid (Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of an interactome network between lncRNAs and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor suppressor

  • Ramírez-Moya, Julia
  • Wert-Lamas, León
  • Acuña-Ruiz, Adrián
  • Fletcher, Alice
  • Wert-Carvajal, Carlos
  • McCabe, Christopher J.
  • Santisteban, Pilar
  • Riesco-Eizaguirre, Garcilaso
Thyroid cancer is the most common primary endocrine malignancy in adults and its incidence is rapidly increasing. Long non-coding RNAs (lncRNAs), generally defined as RNA molecules longer than 200 nucleotides with no protein-encoding capacity, are highly tissue-specific molecules that serve important roles in gene regulation through a variety of different mechanisms, including acting as competing endogenous RNAs (ceRNAs) that ‘sponge’ microRNAs (miRNAs). In the present study, using an integrated approach through RNA-sequencing of paired thyroid tumor and non-tumor samples, we have identified an interactome network between lncRNAs and miRNAs and examined the functional consequences in vitro and in vivo of one of such interactions. We have identified a likely operative post-transcriptional regulatory network in which the downregulated lncRNA, SPTY2D1-AS1, is predicted to target the most abundant and upregulated miRNAs in thyroid cancer, particularly miR-221, a well-known oncomiRNA in cancer. Indeed, SPTY2D1-AS1 functions as a potent tumor suppressor in vitro and in vivo, it is downregulated in the most advanced stages of human thyroid cancer, and it seems to block the processing of the primary form of miR-221. Overall, our results link SPTY2D1-AS1 to thyroid cancer progression and highlight the potential use of this lncRNA as a therapeutic target of thyroid cancer., This work was supported by grants SAF2016-75531-R and PID2019-105303RB-I00/AEI/10.13039/501100011033 from Ministerio de Ciencia e Innovación (MICIN); Fondo Europeo de Desarrollo Regional, B2017/BMD-3724 from Comunidad de Madrid; GCB14142311CRES from Asociación Española contra el Cáncer (AECC); and PI14/01980 from Instituto de Salud Carlos III (Spain). JR-M holds a FPU fellowship from MECD (Spain)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Sox9 is involved in the thyroid differentiation program and is regulated by crosstalk between TSH, TGFβ and thyroid transcription factors

  • López-Márquez, Arístides
  • Carrasco-López, Carlos
  • Martínez-Cano, Andrea
  • Lemoine, Pascale
  • Pierreux, Christophe E.
  • Santisteban, Pilar
While the signaling pathways and transcription factors involved in the differentiation of thyroid follicular cells, both in embryonic and adult life, are increasingly well understood, the underlying mechanisms and potential crosstalk between the thyroid transcription factors Nkx2.1, Foxe1 and Pax8 and inductive signals remain unclear. Here, we focused on the transcription factor Sox9, which is expressed in Nkx2.1-positive embryonic thyroid precursor cells and is maintained from embryonic development to adulthood, but its function and control are unknown. We show that two of the main signals regulating thyroid differentiation, TSH and TGFβ, modulate Sox9 expression. Specifically, TSH stimulates the cAMP/PKA pathway to transcriptionally upregulate Sox9 mRNA and protein expression, a mechanism that is mediated by the binding of CREB to a CRE site within the Sox9 promoter. Contrastingly, TGFβ signals through Smad proteins to inhibit TSH-induced Sox9 transcription. Our data also reveal that Sox9 transcription is regulated by the thyroid transcription factors, particularly Pax8. Interestingly, Sox9 significantly increased the transcriptional activation of Pax8 and Foxe1 promoters and, consequently, their expression, but had no effect on Nkx2.1. Our study establishes the involvement of Sox9 in thyroid follicular cell differentiation and broadens our understanding of transcription factor regulation of thyroid function., This work was supported by grants PID2019-105303RB-I00/AEI/10.13039/501100011033 from Ministerio de Ciencia e Innovación (MICIN), Spain; B2017/BMD-3724 from Comunidad de Madrid, and GCB14142311CRES from Fundación Española Contra el Cáncer (AECC) to PS, and the Actions de Recherche concertées-UCLouvain (ARC 15/20-065), the Fonds pour la Recherche Scientifique (F.R.S-FNRS, # J.0126.16), and Fondation Roi Baudouin to CEP. C.C-L holds a FPI fellowship associated to Grant SAF2016-75531-R/FEDER from MICIN.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

  • Zaballos, Miguel A.
  • Acuña-Ruiz, Adrián
  • Morante, Marta
  • Riesco-Eizaguirre, Garcilaso
  • Crespo, Piero
  • Santisteban, Pilar
Background: RAS-to-ERK signaling is crucial for the onset and progression of advanced thyroid carcinoma, and blocking ERK dimerization provides a therapeutic benefit in several human carcinomas. Here we analyzed the effects of DEL-22379, a relatively specific ERK dimerization inhibitor, on the activation of the RAS-to-ERK signaling cascade and on tumor-related processes in vitro and in vivo. Methods: We used a panel of four human anaplastic thyroid carcinoma (ATC) cell lines harboring BRAF or RAS mutations to analyze ERK dynamics and tumor-specific characteristics. We also assessed the impact of DEL-22379 on the transcriptional landscape of ATC cell lines using RNA-sequencing and evaluated its therapeutic efficacy in an orthotopic mouse model of ATC. Results: DEL-22379 impaired upstream ERK activation in BRAF- but not RAS-mutant cells. Cell viability and metastasis-related processes were attenuated by DEL-22379 treatment, but mostly in BRAF-mutant cells, whereas in vivo tumor growth and dissemination were strongly reduced for BRAF-mutant cells and mildly reduced for RAS-mutant cells. Transcriptomics analyses indicated that DEL-22379 modulated the transcriptional landscape of BRAF- and RAS-mutant cells in opposite directions. Conclusions: Our findings establish that BRAF- and RAS-mutant thyroid cells respond differentially to DEL-22379, which cannot be explained by the previously described mechanism of action of the inhibitor. Nonetheless, DEL-22379 demonstrated significant anti-tumor effects against BRAF-mutant cells in vivo with an apparent lack of toxicity, making it an interesting candidate for the development of combinatorial treatments. Our data underscore the differences elicited by the specific driver mutation for thyroid cancer onset and progression, which should be considered for experimental and clinical approaches., This work was supported by a grant from the Asociación Española Contra el Cancer (AECC; GCB141423113), jointly awarded to PS, PC and GR-E, and by the following national grants: SAF2016-75531-R (MINECO/FEDER, UE); B2017/BMD-3724 Tironet2 (Comunidad de Madrid) and PID2019-105303RB-I00/AEI/10.13.039/501100011033 from MICIN (to PS); RTI2018-096658B-100/AEI from MICIU/FEDER, UE) (to PC); PI14/01980 from Instituto Salud Carlos III (ISCIII) (to GR-E). PS, PC, GR-E and MAZ are members of CIBERONC ISCIII. MAZ, is a postdoctoral researcher funded by grant AECC-GCB141423113; AA-R was funded by an FPI fellowship from MINECO (SAF2013-44709-R) and a postdoctoral fellowship AECC-GCB141423113.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genomic and epigenomic profile of thyroid cancer

  • Acuña-Ruiz, Adrián
  • Carrasco-López, Carlos
  • Santisteban, Pilar
Thyroid cancer is the most common malignancy of the endocrine system, and its incidence has been steadily increasing. Advances in sequencing have allowed analysis of the entire cancer genome, and has provided new information on the genetic lesions and modifications responsible for the onset, progression, dedifferentiation and metastasis of thyroid carcinomas. Moreover, integrated genomics has advanced our understanding of the development of cancer and its behavior, and has facilitated the identification of new genetic mutations and molecular pathways. The functional analysis of epigenetic modifications, such as DNA methylation, histone acetylation and non-coding RNAs, have contributed to define new regulatory mechanisms that control cell malignancy in thyroid cancer, especially aggressive forms. Here we review the most recent advances in genomics and epigenomics of thyroid cancer, which have resulted in a new classification and interpretation of the initiation and progression of thyroid tumors, providing new tools and opportunities for further investigation and for the clinical development of new treatment strategies., This work was supported by grants PID2019-105303RB-I00/AEI/10.13039/501100011033 from the Ministerio de Ciencia e Innovación (MICIN), Spain; B2017/BMD-3724 from Comunidad de Madrid; and GCB14142311CRES from Fundación Española Contra el Cáncer (AECC). A.A-R holds a postdoctoral contract of GCB14142311CRES from Fundación Española Contra el Cáncer (AECC) and C.C-L has an FPI fellowship associated with Grant SAF2016-75531-R/FEDER from MICIN., Peer reviewed